Remdesivir O-desphosphate acetonide impurity
Based on 3 publication(s) in Google Scholar
Remdesivir O-desphosphate acetonide impurity is an impurity of Remdesivir. Remdesivir (GS-5734), a nucleoside analogue with effective antiviral activity and is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro.
For research use only. We do not sell to patients.
- Purity: 99.79%
- CAS No.: 1191237-80-5
- Formula: C15H17N5O4
- Molecular Weight:331.33
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
HY-103586
GS-441524
-
HY-136597R
Remdesivir O-desphosphate acetonide impurity (Standard)
-
HY-138170
ALC-0315
-
HY-104077
Remdesivir
-
HY-143216
Ensitrelvir
-
HY-W076298
Remdesivir intermediate-1
-
HY-16050
Plitidepsin
-
HY-103586R
GS-441524 (Standard)
-
HY-160554
C12-113
-
HY-104077R
Remdesivir (Standard)
-
HY-153377
Lipid 14
-
HY-138170GL
ALC-0315 (GMP Like)
Publications Citing Use of MedChemExpress (MCE) Remdesivir O-desphosphate acetonide impurity
MoreAll DNA/RNA Synthesis Isoforms
More
Biological Activity
Remdesivir O-desphosphate acetonide impurity (analogue 21) is a 2′,3′-acetonide protected analogue of Remdesivir[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1191237-80-5
-
Appearance Solid
-
Molecular Weight 331.33
-
Formula C15H17N5O4
-
Color Off-white to light yellow
-
SMILES
N#C[C@](O1)(C2=CC=C3N2N=CN=C3N)[C@@](OC4(C)C)([H])[C@@](O4)([H])[C@H]1CO
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Nucleic Acids Res
COVID19 Drug Repository: text-mining the literature in search of putative COVID19 therapeutics. [Abstract]2021 Jan 8;49(D1):D1113-D1121. PMID: 33166390 -
J Med Virol
Drug Repurposing: In Vitro Evaluation of Simeprevir as a Novel Antiviral Drug Against Severe Fever With Thrombocytopenia Syndrome Virus. [Abstract]2025 Oct;97(10):e70655. PMID: 41117261 -
Solvent & Solubility
DMSO : 100 mg/mL (301.81 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.55 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.55 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (282 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Dustin Siegel, et al. Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses. J Med Chem. 2017 Mar 9;60(5):1648-1661. [Content Brief]
[2]. Manli Wang, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.0181 mL | 15.0907 mL | 30.1814 mL | 75.4535 mL |
| 5 mM | 0.6036 mL | 3.0181 mL | 6.0363 mL | 15.0907 mL | |
| 10 mM | 0.3018 mL | 1.5091 mL | 3.0181 mL | 7.5453 mL | |
| 15 mM | 0.2012 mL | 1.0060 mL | 2.0121 mL | 5.0302 mL | |
| 20 mM | 0.1509 mL | 0.7545 mL | 1.5091 mL | 3.7727 mL | |
| 25 mM | 0.1207 mL | 0.6036 mL | 1.2073 mL | 3.0181 mL | |
| 30 mM | 0.1006 mL | 0.5030 mL | 1.0060 mL | 2.5151 mL | |
| 40 mM | 0.0755 mL | 0.3773 mL | 0.7545 mL | 1.8863 mL | |
| 50 mM | 0.0604 mL | 0.3018 mL | 0.6036 mL | 1.5091 mL | |
| 60 mM | 0.0503 mL | 0.2515 mL | 0.5030 mL | 1.2576 mL | |
| 80 mM | 0.0377 mL | 0.1886 mL | 0.3773 mL | 0.9432 mL | |
| 100 mM | 0.0302 mL | 0.1509 mL | 0.3018 mL | 0.7545 mL |
Remdesivir O-desphosphate acetonide impurity Related Classifications
HY-136597 Related Classifications
Powered by Bioz